Saffron Bio Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
- Paid Up Capital ₹ 0.10 M
- Company Age 17 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 55.74%
- Profit Growth -180.99%
- Ebitda -55.78%
- Net Worth -2.24%
- Total Assets 20.81%
About Saffron Bio Pharma
Saffron Bio Pharma Private Limited (SBPPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 May 2007 and has a history of 17 years and nine months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Monika Jain and Vishwas Jain serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24233DL2007PTC162828
-
Company No.
162828
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 May 2007
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
What products or services does Saffron Bio Pharma Private Limited offer?
Saffron Bio Pharma Private Limited offers a wide range of products and services, including Pharmaceutical Tablets, Antibiotic Tablets & Capsules, Cefixime Tablet, Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant, Pantoprazole Drugs, Pantoprazole Tablets, Antibacterial Drugs, Ofloxacin Ornidazole Tablets, Anti Inflammatory Drugs.
Who are the key members and board of directors at Saffron Bio Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Monika Jain
|
Director | 01-May-2007 | Current |
|
Vishwas Jain
|
Director | 01-May-2007 | Current |
Financial Performance of Saffron Bio Pharma.
Saffron Bio Pharma Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 55.74% increase. The company also saw a substantial fall in profitability, with a 180.99% decrease in profit. The company's net worth dipped by a decrease of 2.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Saffron Bio Pharma?
In 2017, Saffron Bio Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Saffron Bio Pharma?
Unlock and access historical data on people associated with Saffron Bio Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Saffron Bio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Saffron Bio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.